Clofazimine, a Promising Drug for the Treatment of Babesia microti Infection in Severely Immunocompromised Hosts

Abstract Background Persistent and relapsing babesiosis caused by Babesia microti often occurs in immunocompromised patients, and has been associated with resistance to antimicrobial agents such as atovaquone. Given the rising incidence of babesiosis in the United States, novel drugs are urgently ne...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of infectious diseases 2020-08, Vol.222 (6), p.1027-1036
Hauptverfasser:	Tuvshintulga, Bumduuren, Vannier, Edouard, Tayebwa, Dickson S, Gantuya, Sambuu, Sivakumar, Thillaiampalam, Guswanto, Azirwan, Krause, Peter J, Yokoyama, Naoaki, Igarashi, Ikuo
Format:	Artikel
Sprache:	eng
Schlagworte:	Amino Acid Sequence Animals Antibiotics Antimicrobial agents Atovaquone Babesia microti Babesia microti - drug effects Babesia microti - genetics Babesia microti - immunology Babesiosis Babesiosis - drug therapy Babesiosis - immunology Babesiosis - parasitology Clofazimine Clofazimine - administration & dosage Clofazimine - adverse effects Clofazimine - therapeutic use Cytochrome b Cytochromes b - chemistry Cytochromes b - genetics Disease Models, Animal DNA, Protozoan Dosage Drug Evaluation, Preclinical Drug Resistance Erythrocytes Erythrocytes - parasitology Immunocompromised Host Immunocompromised hosts Leprostatic Agents - administration & dosage Leprostatic Agents - adverse effects Leprostatic Agents - therapeutic use Leprosy Mice Oral administration Parasitemia Parasitemia - parasitology Parasites Polymerase chain reaction Severe combined immunodeficiency Treatment Outcome Tuberculosis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!